MedEasy secures $750,000 in seed funding

In Q3 of FY 2024–25, ACI Limited reported a consolidated loss of Tk 13.69 crore, a sharp decline from a Tk 1.65 crore profit in the same period last year, despite a 17% year-on-year revenue growth to Tk 3,573.50 crore.

In Q3 of FY 2024–25, Renata PLC’s profit fell 20% year-on-year to Tk 58 crore, despite a 16% rise in sales to Tk 1,070 crore, driven by strong domestic demand. However, profits declined due to a 100% surge in finance costs, reaching Tk 45 crore from Tk 23 crore, amid rising interest rates.

In Q3 of FY2024-25, Square Pharmaceuticals reported an 18% year-on-year profit increase, reaching Tk 605 crore, while revenue rose 22% to Tk 2,012 crore. Its EPS climbed to Tk 6.83 from Tk 5.55, and for the July–March period, EPS reached Tk 21.15, up from Tk 18.24.

Two directors of Square Pharmaceuticals, Samuel S Chowdhury and Ratna Patra, each purchased 15 lakh shares, totaling Tk 64.58 crore, based on the DSE’s disclosed closing price of Tk 215.40 per share. These transactions, declared earlier in March, reflect continued confidence in the company, whose shares rose 0.05% during morning trading.

Bangladesh Bank has announced a Tk 9.0 billion startup fund aimed at accelerating economic growth by providing capital to new enterprises. The fund will be distributed through commercial banks and is part of the government's initiative to foster innovation and investment in the startup sector.

Bangladesh has unveiled a series of bold reforms and financial initiatives aimed at easing business operations and energizing the startup ecosystem. At the Bangladesh Investment Summit 2025, the central bank announced a Tk900 crore equity fund dedicated to startups, alongside an additional Tk500 crore fund combining equity and lending support.